Literature DB >> 33206326

Gut-Brain-Skin Axis in Psoriasis: A Review.

Guang Chen1,2, Zai-Ming Chen2, Xiao-Yan Fan1, Yue-Lei Jin1, Xin Li1,3, Shi-Ren Wu2, Wei-Wei Ge2, Cao-Hua Lv2, Yao-Kun Wang3, Jin-Guang Chen4.   

Abstract

INTRODUCTION: Psoriasis is a common skin disease, with chronic inflammation and a complex etiology. It has long been recognized that chronic skin conditions and mental health disorders are often co-morbid. Thus, the concept of the gut-brain-skin axis emphasized in mental health disorders may also regulate the health of skin.
RESULTS: The gut microbiota has been found to be the bridge between the immune system and nervous system. By leveraging clinical cases and animal models of psoriasis, an important communication pathway has been identified along the gut-brain-skin axis that is associated with the modulation of neurotransmitters from the microbiota. Furthermore, mammalian neurotransmitters, including dopamine, serotonin, or γ-aminobutyric acid (GABA), can be produced and/or consumed by several types of bacteria. Other studies suggest that manipulating these neurotransmitters by bacteria may have an effect on host physiology, and the levels of neurotransmitter can be altered by microbiota-based interventions.
CONCLUSIONS: Nonetheless, it is unknown whether or not the manipulation of neurotransmitter levels by bacteria can affect the occurrence and development of psoriasis. Notably, preliminary experiments found that oral consumption of probiotics improves the clinical symptoms in patients with psoriasis, perhaps correlated with the gut microbiome-mediated crosstalk between the immune system and the nervous system by secreting neurotransmitters in psoriasis. In this review, the communication along the gut-brain-skin axis is discussed.

Entities:  

Keywords:  Crosstalk; Gut microbiome; Immune system; Nervous system; Neurotransmitter; Psoriasis

Year:  2020        PMID: 33206326     DOI: 10.1007/s13555-020-00466-9

Source DB:  PubMed          Journal:  Dermatol Ther (Heidelb)


  94 in total

Review 1.  Psoriasis.

Authors:  Michael P Schön; W-Henning Boehncke
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

Review 2.  Psoriasis.

Authors:  Frank O Nestle; Daniel H Kaplan; Jonathan Barker
Journal:  N Engl J Med       Date:  2009-07-30       Impact factor: 91.245

Review 3.  Pathogenesis of psoriasis and development of treatment.

Authors:  Eisaku Ogawa; Yuki Sato; Akane Minagawa; Ryuhei Okuyama
Journal:  J Dermatol       Date:  2017-12-10       Impact factor: 4.005

4.  Oxidative stress involvement in psoriasis: a systematic review.

Authors:  Serafinella Patrizia Cannavò; Gabriella Riso; Marco Casciaro; Eleonora Di Salvo; Sebastiano Gangemi
Journal:  Free Radic Res       Date:  2019-08-08

Review 5.  Psoriasis.

Authors:  Wolf-Henning Boehncke; Michael P Schön
Journal:  Lancet       Date:  2015-05-27       Impact factor: 79.321

6.  IL-33 contributes to disease severity in Psoriasis-like models of mouse.

Authors:  Yaju Duan; Yonghua Dong; Hua Hu; Qiumei Wang; Sheng Guo; Dandan Fu; Xiangfeng Song; Dhan V Kalvakolanu; Zhongwei Tian
Journal:  Cytokine       Date:  2019-03-23       Impact factor: 3.861

Review 7.  The immunogenetics of Psoriasis: A comprehensive review.

Authors:  Jamie L Harden; James G Krueger; Anne M Bowcock
Journal:  J Autoimmun       Date:  2015-07-26       Impact factor: 7.094

8.  Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys.

Authors:  Charles G Helmick; Hyewon Lee-Han; Shawn C Hirsch; Tiffany L Baird; Christopher L Bartlett
Journal:  Am J Prev Med       Date:  2014-04-18       Impact factor: 5.043

Review 9.  Human Leukocyte Antigen-Class I Alleles and the Autoreactive T Cell Response in Psoriasis Pathogenesis.

Authors:  Jörg Christoph Prinz
Journal:  Front Immunol       Date:  2018-04-30       Impact factor: 7.561

Review 10.  The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis.

Authors:  Michael P Schön; Luise Erpenbeck
Journal:  Front Immunol       Date:  2018-06-15       Impact factor: 7.561

View more
  7 in total

Review 1.  The potential action of SSRIs in the treatment of skin diseases including atopic dermatitis and slow-healing wounds.

Authors:  Aneta Kiecka; Marian Szczepanik
Journal:  Pharmacol Rep       Date:  2022-10-07       Impact factor: 3.919

Review 2.  Opioidergic Signaling-A Neglected, Yet Potentially Important Player in Atopic Dermatitis.

Authors:  Dorottya Ádám; József Arany; Kinga Fanni Tóth; Balázs István Tóth; Attila Gábor Szöllősi; Attila Oláh
Journal:  Int J Mol Sci       Date:  2022-04-08       Impact factor: 6.208

Review 3.  Comparative Analysis of the Microbiome across the Gut-Skin Axis in Atopic Dermatitis.

Authors:  Dong Hoon Park; Joo Wan Kim; Hi-Joon Park; Dae-Hyun Hahm
Journal:  Int J Mol Sci       Date:  2021-04-19       Impact factor: 5.923

4.  A Citrus Fruit Extract High in Polyphenols Beneficially Modulates the Gut Microbiota of Healthy Human Volunteers in a Validated In Vitro Model of the Colon.

Authors:  Mônica Maurer Sost; Sanne Ahles; Jessica Verhoeven; Sanne Verbruggen; Yala Stevens; Koen Venema
Journal:  Nutrients       Date:  2021-11-01       Impact factor: 5.717

Review 5.  Exploring the Links between Obesity and Psoriasis: A Comprehensive Review.

Authors:  Gabriela Barros; Pablo Duran; Ivana Vera; Valmore Bermúdez
Journal:  Int J Mol Sci       Date:  2022-07-06       Impact factor: 6.208

Review 6.  Psoriasis and neurodegenerative diseases-a review.

Authors:  Julia Nowowiejska; Anna Baran; Iwona Flisiak
Journal:  Front Mol Neurosci       Date:  2022-09-26       Impact factor: 6.261

Review 7.  The Human Skin Microbiome in Selected Cutaneous Diseases.

Authors:  Silvia Carmona-Cruz; Luz Orozco-Covarrubias; Marimar Sáez-de-Ocariz
Journal:  Front Cell Infect Microbiol       Date:  2022-03-07       Impact factor: 5.293

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.